Evidence map›Paper›PMID 30881027›Full record

ArticleOncoTargets and therapy2019

Dichloroacetic acid upregulates apoptosis of ovarian cancer cells by regulating mitochondrial function.

Li Zhou, Lianlian Liu, Wei Chai, Ting Zhao, Xin Jin, Xinxin Guo, Liying Han, Chunli Yuan

Open access · goldAbstract read
In one paragraph

Article in OncoTargets and therapy, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.

0numbers the graph read from it
0cells of the map it votes in
22citing papers in PubMed
1.5field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

22 citing papers in PubMed, 34 citations in OpenAlex.

  1. Review
  2. Review
  3. Subcellular Stress Markers in Epithelial Ovarian Cancer.International journal of molecular sciences · 2025
    Review
  4. Review
  5. Review
  6. Article
  7. Review
  8. Article
  9. Dichloroacetate for Cancer Treatment: Some Facts and Many Doubts.Pharmaceuticals (Basel, Switzerland) · 2024
    Review
  10. Review
  11. Review
  12. Review
  13. Article
  14. Review
  15. Review
  16. Review
  17. Article
  18. Article
  19. Article
  20. Metabolic reprogramming in epithelial ovarian cancer.American journal of translational research · 2021
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 1 country.

Li ZhouDepartment of Obstetrics and Gynecology, The First Hospital of Jilin University, Changchun 130021, China, 15804302511@163.com.
Lianlian LiuDepartment of Obstetrics and Gynecology, The Second Hospital of Jilin University, Changchun 130041, China, zanghu@163.com.
Wei ChaiDepartment of Obstetrics and Gynecology, The First Hospital of Jilin University, Changchun 130021, China, 15804302511@163.com.
Ting ZhaoDepartment of Obstetrics and Gynecology, The First Hospital of Jilin University, Changchun 130021, China, 15804302511@163.com.
Xin JinDepartment of Obstetrics and Gynecology, Dalian Municipal Women and Children's Medical Center, Dalian 130041, China.
Xinxin GuoDepartment of Obstetrics and Gynecology, The First Hospital of Jilin University, Changchun 130021, China, 15804302511@163.com.
Liying HanDepartment of Obstetrics and Gynecology, The Second Hospital of Jilin University, Changchun 130041, China, zanghu@163.com.
Chunli YuanDepartment of Obstetrics and Gynecology, The First Hospital of Jilin University, Changchun 130021, China, 15804302511@163.com.
Jilin University · CNSecond Affiliated Hospital of Jilin University · CNDalian Medical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundMetabolic reprogramming is a characteristic of tumor cells and is considered a potential therapeutic target. Even under aerobic conditions, tumor cells use glycolysis to produce energy, a phenomenon called the "Warburg effect". Pyruvate dehydrogenase kinase 1 (PDK1) is a key factor linking glycolysis and the tricarboxylic acid cycle. Dichloroacetic acid (DCA) reverses the Warburg effect by inhibition of PDK1 to switch cytoplasmic glucose metabolism to mitochondrial oxidative phosphorylation (OXPHOS).

methodsCell viability was examined using a standard MTT assay. Glucose consumption and l-lactate production were measured using commercial colorimetric kits, and intracellular lactate dehydrogenase (LDH) activity was evaluated using cell lysates and an LDH Quantification Kit. Real-time PCR was used to detect the expression of related genes. The production of total ROS was evaluated by staining with dichlorofluorescin diacetate.

resultsComparison of various aspects of glucose metabolism, such as expression of key enzymes in glycolysis, lactate production, glucose consumption, mitochondrial oxygen consumption rate, and citric acid production, revealed that A2780/DDP cells were primarily dependent on glycolysis whereas A2780 cells were primarily dependent on mitochondrial OXPHOS. Mitochondrial uncoupling protein 2 (UCP2) protects against mitochondrial ROS while allowing energy metabolism to switch to glycolysis. Treatment of A2780 cells with various concentrations of DCA resulted in decreased expression of UCP2, a metabolic switch from glycolysis to mitochondrial OXPHOS, and an increase in oxidative stress induced by ROS. These effects were not observed in A2780/DDP cells with higher UCP2 expression suggesting that UCP2 might induce changes in mitochondrial functions that result in different sensitivities to DCA.

conclusionOur results show that a drug targeting tumor metabolic changes affects almost the entire process of glucose metabolism. Thus, it is necessary to comprehensively determine tumor metabolic functions to facilitate individualized antitumor therapy.

Indexed as

DCAglucoseglycolysismetabolismmitochondrial function

Identifiers

PMID30881027
PMCPMC6419601
OpenAlexW2921473233

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.